CERiS Names Greg Dorn President

Company Offers Leading Solutions for Healthcare Payment Reviews

Greg Dorn Headshot

FORT WORTH, Texas, Aug. 09, 2022 (GLOBE NEWSWIRE) — CERiS, a CorVel company, announced today that Greg Dorn has been named President of CERiS, a leader in payment integrity solutions. Mr. Dorn previously served as Executive Vice President and has been with the organization since 1996.

“Our growth and expansion of services makes it an exciting time at CERiS,” Dorn said. “We are hiring more expertise, investing in systems, and expanding our product offering to continue to be the premier partner to the Payment Integrity market. CERiS remains committed to our customers by driving the best quality results and highest service standards in the industry.”

“He is an exceptional leader and mentor and will lead CERiS well into the future,” said Michael Combs, Chief Executive Officer and President at CorVel.

About CERiS

CERiS, a leader in both prospective and retrospective claims review and repricing, combines clinical expertise and cost containment solutions to ensure the accuracy and transparency in healthcare payments. Accuracy and validation services include itemization review, DRG validation, facility repricing, contract and policy applications, review of implants and devices, and primary payer cost avoidance. Its proprietary universal chargemaster contains billions of charge items from more than 97% of the nation’s hospitals, helping to ensure the accuracy and objectivity of each claim review.

About CorVel

CorVel Corp. applies technology including artificial intelligence, machine learning and natural language processing to enhance the managing of episodes of care and the related health care costs. We partner with employers, third-party administrators, insurance companies and government agencies in managing worker’s compensation and health, auto and liability services. Our diverse suite of solutions combines our integrated technologies with a human touch. CorVel’s customized services, delivered locally, are backed by a national team to support clients as well as their customers and patients.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

All statements included in this press release, other than statements or characterizations of historical fact, are forward-looking statements. These forward-looking statements are based on the Company’s current expectations, estimates and projections about the Company, management’s beliefs, and certain assumptions made by the Company, and events beyond the Company’s control, all of which are subject to change. Such forward-looking statements include, but are not limited to, statements relating to the Company’s payment review services and the Company’s continued investment in these and other innovative technologies, and statements relating to the Company’s service offerings. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause the Company’s actual results to differ materially and adversely from those expressed in any forward-looking statement, including the risk that the impact of the COVID-19 pandemic on our business, results of operations and financial condition is greater than our initial assessment.

The risks and uncertainties referred to above include but are not limited to factors described in this press release and the Company’s filings with the Securities and Exchange Commission, including but not limited to “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended March 31, 2022, and the Company’s Quarterly Report on Form 10-Q for the quarters ended June 30, 2022, and September 30, 2021 and December 31, 2021. The forward-looking statements in this press release speak only as of the date they are made. The Company undertakes no obligation to revise or update publicly any forward-looking statement for any reason. 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7707c73e-982c-44eb-97ec-44ad0e4444f1.